The global SDGL2 market is expected to grow at a significant CAGR during the forecast period (2021-2027). There is a significant demand for drugs such as Jardiance and Farxiga, which in turn, is contributing to the growth of the market. SGLT2 medications are becoming more popular as the global population of people with type 2 diabetes grows. Due to the increasing number of diabetes patients and their need for medications that help reduce high blood glucose levels despite being on a pharmaceutical regimen such as metformin and insulin, the global SGLT2 market has a significant potential for growth. Jardiance is a once-daily oral drug that is used to regulate blood glucose levels in persons with type 2 diabetes. It was first made available in the US in 2014. Jardince is outselling Invokana in terms of sales, with patients preferring it as it reduces the risk of CVD compared to other SGLT2 medicines by assisting the kidneys in removing glucose from the bloodstream. Jardiance was responsible for more than a third of all sales in the global SGLT2 class of drugs.

North America has the highest number of type 2 diabetics. SGLT2 medications are becoming more popular as the global population with type 2 diabetes grows. Jardiance controls half of the SGLT2 market in the US. Empagliflozin (the active pharmaceutical ingredient in Jardiance) is the only diabetic medicine that reduces the risk of CVD death in persons with Type-2 diabetes, according to the American Diabetes Association Standards of Care. Every year, around 1.7 million Americans are diagnosed with diabetes. In addition, the country has the greatest obesity rate, which is a leading cause of type 2 diabetes. The diabetic type 2 population in the country makes about 95% of the total diabetic population. Non-insulin medications account for 53% of the market value of diabetic drugs in the US. 

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Johnson & Johnson Services, Inc., Eli Lilly & Co., and Bristol Myers Squibb Co., among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global SDGL2 Market Report Segmentation

By Drug 

• Invokana

• Jardiance

• Farxiga/Forxiga

• Suglat

Global SDGL2 Market by Region